GlobeNewswire Inc | Aug 5, 2021 07:00AM EDT

August 05, 2021

BELGRADE, Mont., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and operating results for the second quarter ended June 30, 2021.

Second Quarter 2021 Financial Highlights:

-- Revenue for the second quarter of 2021 totaled $15.0 million, an increase of 42% over the prior-year period -- Gross margin in the second quarter of 2021 was 63.5%, compared to 62.2% for the prior-year period -- Loss from operations totaled $0.5 million compared to an operating loss of $0.4 million for the prior-year period -- Net loss incurred in the second quarter of 2021 totaled $0.7 million compared to a net loss of $2.5 million for the prior-year period -- Non-GAAP Adjusted EBITDA for the second quarter of 2021 totaled $0.9 million, compared to $0.3 million for the prior-year period -- Closed $20 million debt refinancing

We are pleased with our second quarter performance reflecting solid revenue growth on a sequential and year-over-year basis driven by the elective spinal procedure market rebound, said Sean Browne, President and CEO of Xtant Medical. During the quarter, we enhanced our long-term prospects with the increase of both our sales force and distribution network. As business conditions continue to normalize, our commercial strategy is focused on creating more selling opportunities while scaling Xtant for growth. With a strong balance sheet and significant capital resources, we continue to invest in our future through the combination of new product introductions, penetration of underserved markets and further distribution network expansion.

Second Quarter 2021 Financial Results

Second quarter 2021 revenue was $15.0 million, an increase of 42% compared to $10.5 million for the same quarter in 2020. The increase in revenue was largely attributed to easing of restrictions associated with the COVID-19 pandemic in our key markets, resulting in an increase in elective procedures.

Gross margin for the second quarter of 2021 was 63.5%, compared to 62.2% for the same period in 2020. The increase is primarily attributable to greater economies of scale.

Operating expenses for the second quarter of 2021 totaled $10.0 million compared to $6.9 million for the second quarter of 2020. The increase was primarily due to the result of increased sales commissions due to higher revenues, legal and stock-based compensation expense, and research and development expenses, partially offset by lower costs during the prior year period for ERP related expenses.

Second quarter 2021 net loss totaled $0.7 million, or $0.01 per share, compared to the second quarter 2020 net loss of $2.5 million, or $0.19 per share.

Non-GAAP Adjusted EBITDA for the second quarter of 2021 totaled $0.9 million, compared to $0.3 million for the prior-year period. The Company defines Adjusted EBITDA as net income/loss from operations before depreciation, amortization and interest expense and provision for income taxes, and as further adjusted to add back in or exclude, as applicable, non-cash compensation, separation related expenses, and litigation settlement reserves. A calculation and reconciliation of Adjusted EBITDA to net loss can be found in the attached financial tables.

Conference Call

Xtant Medical will host a webcast and conference call to discuss the second quarter 2021 financial results on Thursday, August 5 at 9:00 AM ET. To access the webcast, Click Here. To access the conference call, dial 877-407-6184 within the U.S. or 201-389-0877 outside the U.S. A replay of the call will be available at www.xtantmedical.com, under Investor Info.

About Xtant Medical Holdings, Inc.

Xtant Medical Holdings, Inc. (www.xtantmedical.com) is a global medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Xtant people are dedicated and talented, operating with the highest integrity to serve our customers.

The symbols and denote trademarks and registered trademarks of Xtant Medical Holdings, Inc. or its affiliates, registered as indicated in the United States, and in other countries. All other trademarks and trade names referred to in this release are the property of their respective owners.

Non-GAAP Financial Measures

To supplement the Companys consolidated financial statements prepared in accordance with U.S. generally accepted accounting principles (GAAP), the Company uses certain non-GAAP financial measures in this release, including Adjusted EBITDA. Reconciliations of the non-GAAP financial measures used in this release to the most comparable GAAP measures for the respective periods can be found in tables later in this release. The Companys management believes that the presentation of these measures provides useful information to investors. These measures may assist investors in evaluating the Companys operations, period over period. Management uses the non-GAAP measures in this release internally for evaluation of the performance of the business, including the allocation of resources. Investors should consider non-GAAP financial measures only as a supplement to, not as a substitute for or as superior to, measures of financial performance prepared in accordance with GAAP.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements that are predictive in nature, that depend upon or refer to future events or conditions, or that include words such as intends, expects, anticipates, plans, believes, estimates, continue, future, will, potential, going forward, similar expressions or the negative thereof, and the use of future dates. Forward-looking statements in this release include the Companys continued investment in its future through the combination of new product introductions, penetration of underserved markets and further distribution network expansion. The Company cautions that its forward-looking statements by their nature involve risks and uncertainties, and actual results may differ materially depending on a variety of important factors, including, among others: the Companys future operating results and financial performance; the ability to increase or maintain revenue; the ability to remain competitive; the ability to innovate and develop new products; the ability to engage and retain new and existing independent distributors and qualified personnel; the effect of the COVID-19 pandemic on the Companys business, operating results and financial condition; the Companys ability to implement successfully its future growth initiatives; government and third-party coverage and reimbursement for Company products; the ability to obtain and maintain regulatory approvals and comply with government regulations; the effect of product liability claims and other litigation to which the Company may be subject; the effect of product recalls and defects; the ability to obtain and protect Company intellectual property and proprietary rights and operate without infringing the rights of others; the ability to service Company debt, comply with its debt covenants and access additional indebtedness; the ability to obtain additional financing on favorable terms or at all; and other factors. Additional risk factors are contained in the Companys Annual Report on Form 10-K for the year ended December 31, 2020 filed with the Securities and Exchange Commission (SEC) on February 24, 2021 and subsequent SEC filings by the Company, including without limitation its most recent Quarterly Report on Form 10-Q for the quarter ended June 30, 2021 anticipated to be filed with the SEC. Investors are encouraged to read the Companys filings with the SEC, available at www.sec.gov, for a discussion of these and other risks and uncertainties. The Company undertakes no obligation to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by this cautionary statement.

Investor Relations Contact

David CareyLazar FINNPh: 212-867-1762Email: david.carey@finnpartners.com

XTANT MEDICAL HOLDINGS, INC.CONDENSED CONSOLIDATED BALANCE SHEETS(In thousands, except number of shares and par value) As of June As of 30, 2021 December 31, 2020 ASSETS Current Assets: Cash and cash equivalents $ 20,312 $ 2,341 Restricted Cash 215 - Trade accounts receivable, net of allowance forcredit losses and doubtful accounts of $470 and 6,985 6,880 $653, respectivelyInventories 21,093 21,408 Prepaid and other current assets 827 736 Total current assets 49,432 31,365 Property and equipment, net 4,869 4,347 Right-of -use asset, net 1,477 1,690 Goodwill 3,205 3,205 Intangible assets, net 428 457 Other assets 265 402 Total Assets $ 59,676 $ 41,466 LIABILITIES & STOCKHOLDERS' EQUITY (DEFICIT) Current Liabilities: Accounts payable $ 2,639 $ 2,947 Accrued liabilities 5,728 5,462 Current portion of lease liability 441 423 Finance lease obiligations 30 20 Line of credit 4,077 - - 16,797 Total current liabilities 12,915 25,649 Long-term Liabilities: Lease liability, less current portion 1,076 1,303 Finance lease obligations, less current portion 118 - Long-term debt, plus premium and less issuance 11,683 - costs Total Liabilities 25,792 26,952 Stockholders' Equity (Deficit) Preferred stock, $0.000001 par value; 10,000,000shares authorized; no shares issued and - - outstandingCommon stock, $0.000001 par value; 300,000,000shares authorized; 86,707,286 shares issued andoutstanding as of June 30, 2021 and 77,573,680 - - shares issued and outstanding as of December 31,2020Additional paid-in capital 264,981 244,850 Accumulated deficit (231,097 ) (230,336 )Total Stockholders? Equity (Deficit) 33,884 14,514 Total Liabilities & Stockholders? Equity $ 59,676 $ 41,466 (Deficit)

XTANT MEDICAL HOLDINGS, INC.CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(Unaudited, in thousands, except number of shares and per share amounts) Three Months Ended June 30, Six Months Ended June 30, 2021 2020 2021 2020 Revenue Orthopedic $ 14,942 $ 10,493 $ 27,451 $ 25,227 product salesOther revenue 33 36 66 80 Total revenue 14,975 10,529 27,517 25,307 Cost of sales 5,460 3,979 9,911 9,144 Gross profit 9,515 6,550 17,606 16,163 Gross profit % 63.5 % 62.2 % 64.0 % 63.9 % Operating expensesGeneral and 4,173 2,931 7,200 7,250 administrativeSales and 5,590 3,895 10,445 10,309 marketingResearch and 243 111 458 353 developmentTotaloperating 10,006 6,937 18,103 17,912 expenses Income (Loss)from (491 ) (387 ) (497 ) (1,749 )operations Other income Interest (199 ) (2,054 ) (201 ) (3,163 )expenseTotal Other (199 ) (2,054 ) (201 ) (3,163 )Expense Net LossBefore (690 ) (2,441 ) (698 ) (4,912 )Provision forIncome Taxes Provision for (43 ) (23 ) (64 ) (45 )income taxesNet Loss $ (733 ) $ (2,464 ) $ (762 ) $ (4,957 ) Net loss per share:Basic $ (0.01 ) $ (0.19 ) $ (0.01 ) $ (0.38 )Dilutive $ (0.01 ) $ (0.19 ) $ (0.01 ) $ (0.38 ) Shares used inthe computation:Basic 86,707,286 13,223,565 83,993,159 13,199,455 Dilutive 86,707,286 13,223,565 83,993,159 13,199,455

XTANT MEDICAL HOLDINGS, INC.CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(Unaudited, in thousands) Six Months Ended June 30,

2021 2020 Operating activities: Net loss $ (762 ) $ (4,957 )Adjustments to reconcile net loss to net cash provided by operating activities:Depreciation and amortization 731 1,153 Gain on disposal of fixed assets (108 ) (118 )Non-cash interest 16 3,149 Non-cash rent expense 5 8 Stock-based compensation 921 489 Provision for reserve on accounts receivable (143 ) 204 Provision for excess and obsolete inventory 211 377 Changes in operating assets and liabilities: Accounts receivable 38 2,290 Inventories 104 (4,164 )Prepaid and other assets (29 ) (153 )Accounts payable (308 ) 1,067 Accrued liabilities 266 (921 )Net cash provide by (used in) operating activities 942 (1,576 )Investing activities: Purchases of property and equipment (1,079 ) (673 )Proceeds from sale of fixed assets 125 106 Net cash used in investing activities (954 ) (567 )Financing activities: Payments on financing leases (34 ) (75 )Costs associated with refinancing (105 ) - Payments on long-term debt (411 ) - Borrowings on line of credit 9,331 Repayments of line of credit (9,009 ) - Proceeds from private placement, net of cash 18,426 - issuance costsNet cash used in financing activities 18,198 (75 ) Net change in cash and cash equivalents 18,186 (2,218 )Cash and cash equivalents at beginning of period 2,341 5,237 Cash and cash equivalents at end of period $ 20,527 $ 3,019 Reconciliation of cash and restricted cashreported in the condensed consolidated balance sheetsCash and cash $ 20,312 $ 3,019 equivelantsRestricted cash 215 - Total cash and restricted cash reported in the $ 20,527 $ 3,019 condensed consolidated balance sheets

XTANT MEDICAL HOLDINGS, INC.CALCULATION OF NON-GAAP CONSOLIDATED EBITDA AND ADJUSTED EBITDA(Unaudited, in thousands) Three Months Ended June Six Months Ended June 30, 30, 2021 2020 2021 2020 Net Loss $ (733 ) $ (2,464 ) $ (762 ) $ (4,957 ) Other expense 5 1 42 6 Depreciation and 357 468 731 1,153 amortizationInterest expense 199 2,054 201 3,163 Tax expense 43 23 64 45 Non-GAAP EBITDA (129 ) 82 276 (590 ) Non-GAAP EBITDA/ -0.9 % 0.8 % 1.0 % -2.3 %Total revenue NON-GAAP ADJUSTED EBITDA CALCULATIONNon-cash 465 219 921 489 compensationSeparation-related - - - 749 expensesLitigation reserve 550 - 550 - Non-GAAP Adjusted $ 886 $ 301 $ 1,747 $ 648 EBITDA Non-GAAP AdjustedEBITDA/Total 5.9 % 2.9 % 6.3 % 2.6 %revenue